First Trust Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.52M | Buy |
140,207
+93,580
| +201% | +$4.49M | ﹤0.01% | 1425 |
|
|
2026
Q1 | $2.41M | Buy |
46,627
+16,823
| +56% | +$857K | ﹤0.01% | 1835 |
|
|
2025
Q4 | $1.48M | Sell |
29,804
-41,054
| -58% | -$2M | ﹤0.01% | 2016 |
|
|
2025
Q3 | $3.39M | Sell |
70,858
-18,231
| -20% | -$734K | ﹤0.01% | 1578 |
|
|
2025
Q2 | $2.81M | Buy |
89,089
+16,791
| +23% | +$538K | ﹤0.01% | 1669 |
|
|
2025
Q1 | $2.37M | Buy |
72,298
+45,279
| +168% | +$1.6M | ﹤0.01% | 1712 |
|
|
2024
Q4 | $977K | Sell |
27,019
-25,048
| -48% | -$882K | ﹤0.01% | 2072 |
|
|
2024
Q3 | $1.62M | Buy |
52,067
+30,574
| +142% | +$954K | ﹤0.01% | 1840 |
|
|
2024
Q2 | $575K | Sell |
21,493
-29,297
| -58% | -$849K | ﹤0.01% | 2098 |
|
|
2024
Q1 | $1.73M | Sell |
50,790
-4,282
| -8% | -$127K | ﹤0.01% | 1795 |
|
|
2023
Q4 | $1.59M | Buy |
55,072
+3,829
| +7% | +$102K | ﹤0.01% | 1816 |
|
|
2023
Q3 | $1.41M | Buy |
51,243
+16,372
| +47% | +$498K | ﹤0.01% | 1835 |
|
|
2023
Q2 | $1.05M | Buy |
34,871
+19,330
| +124% | +$676K | ﹤0.01% | 1966 |
|
|
2023
Q1 | $563K | Buy |
15,541
+771
| +5% | +$29.6K | ﹤0.01% | 2107 |
|
|
2022
Q4 | $527K | Sell |
14,770
-45,821
| -76% | -$1.59M | ﹤0.01% | 2172 |
|
|
2022
Q3 | $2.05M | Sell |
60,591
-5,621
| -8% | -$183K | ﹤0.01% | 1662 |
|
|
2022
Q2 | $1.92M | Buy |
+66,212
| New | +$1.9M | ﹤0.01% | 1737 |
|
|
2021
Q4 | – | Sell |
-110,227
| Closed | -$2.94M | – | 2590 |
|
|
2021
Q3 | $2.94M | Sell |
110,227
-91,261
| -45% | -$2.45M | ﹤0.01% | 1608 |
|
|
2021
Q2 | $6.2M | Buy |
201,488
+118,394
| +142% | +$3.63M | 0.01% | 1213 |
|
|
2021
Q1 | $2.17M | Buy |
83,094
+4,574
| +6% | +$128K | ﹤0.01% | 1690 |
|
|
2020
Q4 | $1.98M | Buy |
78,520
+16,032
| +26% | +$345K | ﹤0.01% | 1585 |
|
|
2020
Q3 | $1.3M | Buy |
62,488
+3,093
| +5% | +$70.2K | ﹤0.01% | 1620 |
|
|
2020
Q2 | $1.41M | Buy |
+59,395
| New | +$1.31M | ﹤0.01% | 1568 |
|
|
2020
Q1 | – | Sell |
-18,868
| Closed | -$448K | – | 2423 |
|
|
2019
Q4 | $448K | Buy |
18,868
+3,841
| +26% | +$93.3K | ﹤0.01% | 2149 |
|
|
2019
Q3 | $413K | Sell |
15,027
-532
| -3% | -$15.8K | ﹤0.01% | 2191 |
|
|
2019
Q2 | $515K | Buy |
15,559
+2,036
| +15% | +$69.8K | ﹤0.01% | 2106 |
|
|
2019
Q1 | $474K | Sell |
13,523
-18,618
| -58% | -$693K | ﹤0.01% | 2140 |
|
|
2018
Q4 | $1.07M | Sell |
32,141
-60,999
| -65% | -$2.62M | ﹤0.01% | 1806 |
|
|
2018
Q3 | $4.69M | Buy |
93,140
+16,202
| +21% | +$800K | 0.01% | 1177 |
|
|
2018
Q2 | $4.61M | Buy |
76,938
+41,658
| +118% | +$2.16M | 0.01% | 1142 |
|
|
2018
Q1 | $1.62M | Sell |
35,280
-7,279
| -17% | -$304K | ﹤0.01% | 1585 |
|
|
2017
Q4 | $1.7M | Sell |
42,559
-13,817
| -25% | -$546K | ﹤0.01% | 1612 |
|
|
2017
Q3 | $2.25M | Buy |
+56,376
| New | +$2.44M | 0.01% | 1393 |
|
|
2017
Q2 | – | Sell |
-58,029
| Closed | -$1.82M | – | 2436 |
|
|
2017
Q1 | $1.82M | Sell |
58,029
-17,889
| -24% | -$479K | 0.01% | 1555 |
|
|
2016
Q4 | $1.92M | Buy |
75,918
+66,010
| +666% | +$1.47M | 0.01% | 1479 |
|
|
2016
Q3 | $245K | Sell |
9,908
-92
| -0.9% | -$2.08K | ﹤0.01% | 2185 |
|
|
2016
Q2 | $204K | Sell |
10,000
-31,628
| -76% | -$561K | ﹤0.01% | 2174 |
|
|
2016
Q1 | $635K | Sell |
41,628
-124,017
| -75% | -$1.62M | ﹤0.01% | 1850 |
|
|
2015
Q4 | $2.23M | Sell |
165,645
-31,045
| -16% | -$480K | 0.01% | 1329 |
|
|
2015
Q3 | $2.76M | Buy |
+196,690
| New | +$3.66M | 0.01% | 1219 |
|
Other funds holding SUPN
AC
NAMI
SIMG
First Trust Advisors's SUPN Position: Q2 2026 in Review
First Trust Advisors increased its Supernus Pharmaceuticals (SUPN) stake by 201% in Q2 2026, buying an estimated $4.49M and bringing the position to 140,207 shares worth $6.52M. The position accounts for ﹤0.01% of the portfolio, ranked #1425.
First Trust Advisors first reported a position in SUPN in Q3 2015 and has held it in 40 quarters since. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.
- First Trust Advisors held 140,207 shares of Supernus Pharmaceuticals worth $6.52M as of Q2 2026.
- First Trust Advisors bought 93,580 Supernus Pharmaceuticals shares in Q2 2026, an estimated $4.49M.
- Supernus Pharmaceuticals made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #1425 holding.
- First Trust Advisors first reported a position in Supernus Pharmaceuticals in Q3 2015 and has held it in 40 quarters since.
- 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.
Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.